Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 3
2004 3
2006 4
2007 7
2008 4
2009 3
2010 15
2011 8
2012 12
2013 13
2014 8
2015 10
2016 12
2017 9
2018 4
2019 7
2020 1
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.
Earliest functional declines in Huntington disease.
Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS; Huntington Study Group Investigators. Beglinger LJ, et al. Psychiatry Res. 2010 Jul 30;178(2):414-8. doi: 10.1016/j.psychres.2010.04.030. Epub 2010 May 15. Psychiatry Res. 2010. PMID: 20471695 Free PMC article.
Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset.
McAllister B, Donaldson J, Binda CS, Powell S, Chughtai U, Edwards G, Stone J, Lobanov S, Elliston L, Schuhmacher LN, Rees E, Menzies G, Ciosi M, Maxwell A, Chao MJ, Hong EP, Lucente D, Wheeler V, Lee JM, MacDonald ME, Long JD, Aylward EH, Landwehrmeyer GB, Rosser AE; REGISTRY Investigators of the European Huntington’s disease network; Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group; Williams NM, Gusella JF, Monckton DG, Allen ND, Holmans P, Jones L, Massey TH. McAllister B, et al. Nat Neurosci. 2022 Apr;25(4):446-457. doi: 10.1038/s41593-022-01033-5. Epub 2022 Apr 4. Nat Neurosci. 2022. PMID: 35379994 Free PMC article.
Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1.
Lobanov SV, McAllister B, McDade-Kumar M, Landwehrmeyer GB, Orth M, Rosser AE; REGISTRY Investigators of the European Huntington’s disease network; Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group; Lee JM, MacDonald ME, Gusella JF, Long JD, Ryten M, Williams NM, Holmans P, Massey TH, Jones L. Lobanov SV, et al. NPJ Genom Med. 2022 Sep 5;7(1):53. doi: 10.1038/s41525-022-00317-w. NPJ Genom Med. 2022. PMID: 36064847 Free PMC article.
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, Gudesblatt M, Hunter C, Jankovic J, Kostyk SK, Kumar R, Loy C, Mallonee W, Oakes D, Scott BL, Sung V, Goldstein J, Vaughan C, Testa CM; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators. Frank S, et al. JAMA Neurol. 2017 Aug 1;74(8):977-982. doi: 10.1001/jamaneurol.2017.1352. JAMA Neurol. 2017. PMID: 28692723 Free PMC article.
Movement sequencing in Huntington disease.
Georgiou-Karistianis N, Long JD, Lourens SG, Stout JC, Mills JA, Paulsen JS; Predict-Hd Investigators and Coordinators Of The Huntington Study Group (Hsg). Georgiou-Karistianis N, et al. World J Biol Psychiatry. 2014 Aug;15(6):459-71. doi: 10.3109/15622975.2014.895042. Epub 2014 Mar 28. World J Biol Psychiatry. 2014. PMID: 24678867 Free PMC article.
117 results